- 主辦 / 主持人
- 社團法人中華民國心臟學會
- 積分
- B類 3 分
- 分類
- 未分類
- 聯絡人
- 社團法人中華民國心臟學會 02-25976177~8#17 MS.黃
- 活動日期
- 2024-07-27 (六) 14:00 ~ 17:30
- 地點
- 台北張榮發會議中心803會議室 + 線上
- 說明
- The prostacyclin (prostaglandin I2 (PGI2)) pathway is an important therapeutic target in pulmonary arterial hypertension (PAH). Reduced levels of PGI2 are associated with pathogenic changes within the lung vasculature and therapies that aim to restore PGI2 signalling have been shown to play a key role in PAH management . Evidence to support the use of therapies targeting the PGI2 pathway was first generated in the 1990s when intravenous epoprostenol, was demonstrated to provide symptomatic and haemodynamic benefits and to improve survival. As a result, epoprostenol was the first drug to be approved for PAH. The European Society of Cardiology/European Respiratory Society (ESC/ERS) guidelines cite different levels of recommendation and evidence for each therapy, with epoprostenol having the highest level (IA) in patients with WHO FC III or IV disease. Intravenous prostanoids require continuous infusion via a central venous catheter due to their short half-lives . Serious side-effects may occur on interruption or withdrawal of i.v. prostanoids , which can result from pump malfunctions or if the line is erroneously compromised. A compromised line can lead to cardiovascular collapse
摘要檔案: AB all.pdf
2024-07-27 台北張榮發會議中心803會議室 + 線上
| 時間 | 主題 | |
|---|---|---|
| 沒有資料 | ||